Bioinformatics of Brain Diseases

219

[61] I. S. Piras, M. Manchia, M. J. Huentelman, et al., “Peripheral biomark-

ers in schizophrenia: A meta-analysis of microarray gene expression

datasets,” International Journal of Neuropsychopharmacology, vol. 22,

pp. 186–193, 2018.

[62] J. Choi, D. F. Bodenstein, J. Geraci, et al., “Evaluation of postmortem

microarray data in bipolar disorder using traditional data comparison

and artificial intelligence reveals novel gene targets,” Journal of psychi-

atric research, vol. 142, pp. 328–336, 2021.

[63] H. Hodges, C. Fealko, and N. Soares, “Autism spectrum disorder: defi-

nition, epidemiology, causes, and clinical evaluation,” Translational Pe-

diatrics, vol. 9, pp. S55–S65, 2020.

[64] O. Fajarda, J. R. Almeida, S. Duarte-Pereira, et al., “Methodology to

identify a gene expression signature by merging microarray datasets,”

Computers in biology and medicine, vol. 159, p. 106867, 2023.

[65] T. Sevimoglu, “In silico analysis of autism spectrum disorder through

the integration of dna methylation and gene expression data for

biomarker search,” Minerva Biotechnology and Biomolecular Research,

vol. 35, no. 2, pp. 73–80, 2023.

[66] J. Cabana-Domínguez, M. S. Artigas, L. Arribas, et al., “Comprehensive

analysis of omics data identifies relevant gene networks for attention-

deficit/hyperactivity disorder (adhd),” Translational Psychiatry, vol. 12,

2022.

[67] N. Mortimer, C. Sánchez-Mora, P. Rovira, et al., “Transcriptome pro-

filing in adult attention-deficit hyperactivity disorder,” European Neu-

ropsychopharmacology, vol. 41, pp. 160–166, 2020.

[68] S. Darmanis, S. A. Sloan, D. Croote, et al., “Single-cell rnaseq analysis

of infiltrating neoplastic cells at the migrating front of human glioblas-

toma,” bioRxiv, 2017.

[69] S. Wan, U. A. E. Moure, R. Liu, and C. L. others, “Combined bulk

rna-seq and single-cell rna-seq identifies a necroptosis-related prognos-

tic signature associated with inhibitory immune microenvironment in

glioma,” Frontiers in Immunology, vol. 13, 2022.

[70] P. K. Brastianos, P. Horowitz, S. Santagata, et al., “Genomic sequencing

of meningiomas identifies oncogenic smo and akt1 mutations,” Nature

genetics, vol. 45, pp. 285–289, 2013.

[71] M. S. Abedalthagafi, W. L. Bi, A. A. Aizer, et al., “Oncogenic pi3k

mutations are as common as akt1 and smo mutations in meningioma,”

Neuro-oncology, vol. 18 5, pp. 649–55, 2016.